Navigation Links
Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Date:7/17/2008

SOUTH SAN FRANCISCO, Calif., July 17 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has begun a Phase 2 clinical trial of Adlea(TM), the company's long-acting, site specific, non-opioid drug candidate for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

Adlea is currently in two pivotal Phase 3 trials in the U.S.: one in total knee replacement surgeries and one in bunionectomy surgeries. An additional Phase 2 Adlea trial is in progress in total hip replacement surgeries. These trials are among those intended to support an Adlea label indication for the management of acute pain following orthopedic surgery.

The Phase 2 arthroscopic shoulder surgery trial is being conducted in South Korea. Unlike the United States, where the procedure is often conducted on an outpatient basis, arthroscopic shoulder surgery patients in South Korea are routinely hospitalized for up to two days, thus allowing more extensive near-term follow-up.

"We believe Adlea holds promise for treating pain associated with a number of orthopedic surgical indications, and may reduce the need for other pain treatments such as opioids," said Michael L. Kranda, Anesiva's president and chief executive officer. "As we pursue a broad indication of management of post-surgical pain following orthopedic procedures, each specific procedure that we can evaluate will add to the breadth of available data for Adlea."

Arthroscopic surgery is performed through small incisions using an arthroscope, or camera, to visualize the inside of a joint. Through the incisions, a surgeon inserts a camera and small instruments to perform the procedure. According to the American Aca
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Defines Regulatory Pathway for Adlea with FDA
7. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
8. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... may seem like an odd pairing: an oral growth hormone-boosting ... two of the most talked about topics at ENDO 2013, ... that just convened in San Francisco . ... the top internal medicine experts in the world is very ... not only save lives, but help people feel and ...
(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package.  This three-in-one device allows ... in their designs - cutting installation time by ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Three-in-One X3130 Appliance Inlet Module 2
... PINE BROOK, N.J. and BASEL, Switzerland , ... an agreement for the scale-up and commercial production of Anthim, ... of inhaled anthrax. Under the new contract, Lonza will provide ... of its facilities in the USA . The manufacturing ...
... , July 15 The ... Dermatology (JDD ), a full-color, peer-reviewed publication serving the dermatology ... and tolerability of the active ingredient in PyratineXR™.  The results ... the flagship product in the new advanced skincare line that ...
Cached Medicine Technology:Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development 2Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development 3Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development 4Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology 2Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology 3Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology 4Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology 5
(Date:6/19/2013)... 19, 2013 Amerinet, Inc, a ... Healthcare Technologies to help Pacific Medical Centers implement ... of more than 17 percent over the organization’s ... , “Driving economies of scale and process standardization ... challenges facing multi-site providers,” said Shawn Padilla, director ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical ... the publication of the National Osteoporosis Guideline Group ... osteoporosis in postmenopausal women and older men in ... 2009 in Maturitas , the original guidelines ... timely with an additional focus on the management ...
(Date:6/19/2013)... June 19, 2013 Imprivata ®, ... today announced that Imprivata OneSign ® leads the ... Mid-Term Performance Review: Software & Services report . CIOs ... Imprivata on the superior performance of its products and ... they indicate that Imprivata is integral to their long-term ...
(Date:6/19/2013)... 2013 According to Transparency Market Research ... Trends, Analysis and Forecast, 2011 – 2017,” the global ... the year 2011 and is expected to reach USD ... 9.7% from 2011 to 2017. Flexible endoscopes formed the ... USD 2,201 million for the year 2011. , Related ...
(Date:6/19/2013)... Despite the fact that the incidence of cancer is ... age, we still have an inadequate understanding on how ... though elderly patients are occasionally included in clinical trials, ... ,healthy, (fit) elderly patients. Thus, the broader elderly patient ... EORTC Cancer in the Elderly Task Force is now ...
Breaking Medicine News(10 mins):Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
... of humour or great look is whats really needed to make ... poll by online dating agency Match.com reveals that one in three ... ,Eight out of the ten people who answered the ... was likely to mean the end of a relationship. ...
... Nations World Food Programme (WFP) has warned that continuing security ... especially in the west of the country where food stocks ... may soon see critical food supplies curtailed or interrupted. ... western region of Afghanistan for four weeks due to insecurity. ...
... shown that bone marrow stem cells injected into a ... hearing loss. ,Hearing loss has many ... complete or partial. Such loss may involve damage to ... to inner ear function. ,Some natural regeneration ...
... of 2,785 college students indicates that more than half of ... not seek help and studies show that the incidence of ... is despite the fact that resources are available at no ... University of Michigan School of Public Health. Eisenberg and doctoral ...
... Regulation Ministerial Council (ANZFRMC) has responded to calls from the ... folate fortification of flour for bread making. ,ANZFRMC now ... bread making to be implemented by 2009. ,Chair ... Thomas, said today that the AMA has been calling for ...
... to finding a cure and developing new, effective drugs to ... in New South Wales each year. ,The new research ... undertake crucial research in cancer. It is the largest ... for Australia. ,The centre, an Australian first to establish ...
Cached Medicine News:Health News:Insecurity Jepardising WFP Initiatives in Western Afghanistan 2Health News:Stem Cells Aid in Hearing Recovery 2Health News:A New Survey -Anxiety Students Dont Seek Help 2Health News:New Research Centre at Sydney to Lead Cancer Fight 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: